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ABSTRACT Vancomycin-resistant Enterococcus faecium (VREfm) bloodstream infections
are associated with high recurrence rates. This study used genome sequencing to accu-
rately distinguish the frequency of relapse and reinfection in patients with recurrent E.
faecium bacteremia and to investigate strain relatedness in patients with apparent
VREfm and vancomycin-susceptible E. faecium (VSEfm) mixed infection. A retrospective
study was performed at the Cambridge University Hospitals NHS Foundation Trust (CUH)
between November 2006 and December 2012. We analyzed the genomes of 44 E. fae-
cium isolates from 21 patients (26 VREfm isolates from 12 patients with recurrent bacte-
remia and 18 isolates from 9 patients with putative VREfm/VSEfm mixed infection). Phe-
notypic antibiotic susceptibility was determined using a Vitek2 instrument. Genomes
were compared with those of a further 263 E. faecium isolates associated with bactere-
mia in patients at CUH over the same time period. Pairwise comparison of core ge-
nomes indicated that 10 (71%) episodes of recurrent VREfm bacteremia were due to re-
infection with a new strain, with reinfection being more likely with increasing time
between the two positive cultures. The majority (78%) of patients with a mixed VREfm
and VSEfm infection had unrelated strains. More than half (59%) of study isolates were
closely related to another isolate associated with bacteremia from CUH. This included
60% of isolates associated with reinfection, indicating acquisition in the hospital. This
study provides the ﬁrst high-resolution insights into recurrence and mixed infection by
E. faecium and demonstrates that reinfection with a new strain, often acquired from the
hospital, is a driver of recurrence.
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Enterococcus faecium is an important cause of bloodstream infections in critically illand immunocompromised patients (1) and ranks among the 10 most common
microorganisms associated with health care-associated infections in the United States
(2). Bacteremia caused by vancomycin-resistant enterococci is associated with in-
creased mortality, costs of care, and rates of recurrence compared to levels for
vancomycin-susceptible strains (3–5).
Despite the establishment of linezolid and daptomycin as mainstay therapeutic
agents for vancomycin-resistant E. faecium (VREfm) bacteremia since the early 2000s,
recurrence remains a common clinical challenge, with rates ranging from 3% to 25%
(6–8). Following apparent clearance of infection, recurrent bacteremia can be explained
by either relapsing infection with the same strain due to a persistent focus of infection
or reinfection with the same or a different strain. Differentiating between these
scenarios is clinically relevant; relapsing infection requires investigation and interven-
tions to deal with a persistent focus of infection, while reinfection is more likely to be
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associated with an underlying susceptibility that increases the risk of invasion due to
breakdown of host immune defenses. Surprisingly little is known about the relative
frequency of relapse versus reinfection in recurrent E. faecium bacteremia, with the
literature limited to case reports (9–11) and case series predominantly limited to
patients with Enterococcus faecalis infection (12, 13).
E. faecium bacteremia is polymicrobial in up to 35% of cases due to mixed infection with
other bacterial genera or enterococcal species (14). Apparent mixed infection with VREfm
and vancomycin-susceptible E. faecium (VSEfm) has been reported in the context of in vivo
loss or gain of the van transposon by subpopulations of the same strain (15–17). However,
while carriage of multiple strains of E. faecium is presumed to be common (18, 19), the
frequency of mixed infection with different E. faecium strains is unknown.
Whole-genome sequencing has demonstrated discriminatory power superior to that
of traditional bacterial typing techniques such as pulsed-ﬁeld gel electrophoresis (PFGE)
or multilocus sequence typing (MLST) in epidemiological investigations and in studies
of the population structure of E. faecium causing bacteremia at local and national levels
(20–23). Here, we use genome sequencing to gain a better understanding of E. faecium
bacteremia. Speciﬁcally, we investigated strain relatedness in patients with recurrent
VREfm bacteremia and in patients with apparent mixed bloodstream infection with
VREfm and VSEfm. In addition, we compared the ﬁndings of genome sequencing with
antibiotic resistance proﬁles.
MATERIALS AND METHODS
A retrospective study was conducted at the Cambridge University Hospitals NHS Foundation Trust
(CUH), a tertiary referral center in the United Kingdom with 1,170 beds and 350,000 occupied-bed-days
per year. The rate of vancomycin resistance in E. faecium bacteremia isolates at CUH is high (60%),
approaching rates reported in the United States (2), and historical data from 2001 suggest that 32.6% of
patients at CUH in high-risk wards carry VRE (either E. faecium or E. faecalis) (26).
All patients with VREfm bloodstream infection between November 2006 and December 2012 were
identiﬁed using the diagnostic microbiology laboratory database. These cases were evaluated to identify all
patients with (i) recurrence of VREfm bloodstream infection and/or (ii) putative mixed VREfm and VSEfm
bloodstream infection. Recurrence was deﬁned as a blood culture that was positive for VREfm taken30 days
after the index culture from a patient with intervening negative blood cultures and/or resolution of clinical
signs of infection. Putativemixed VREfm and VSEfm infection was deﬁned as the isolation of VREfm and VSEfm
from the same blood culture or different cultures taken within 48 h of the index sample.
Fourteen patients fulﬁlled the criterion for recurrence, and 10 patients fulﬁlled the criterion for
putative mixed VREfm and VSEfm infection, with no overlap of cases between the two groups. Seven of
the patients had mixed infection with other bacterial species, as shown in Data Set S1 in the supple-
mental material. Cross-referencing these 24 patients with the bacterial freezer archive identiﬁed 44
isolates from 21 patients (12 patients with recurrence and 9 patients with mixed VREfm and VSEfm
infection), who were the basis for this study. Clinical data for the 21 cases were collected from paper and
computerized medical records using a standardized form, including the suspected focus of infection,
underlying comorbidities, and dates of positive and negative blood cultures. Neutropenia was deﬁned as
a polymorphonuclear leukocyte count of less than 500 cells/l within 24 h of the onset of bacteremia.
The focus of infection was deﬁned based on clinical, radiological, and microbiological features. Bacte-
remia was determined to be secondary to an intravascular device (i) if a positive intravascular catheter
tip semiquantitative culture yielded more than 15 CFU of E. faecium with an antibiogram identical to that
of the blood culture isolate (deﬁnite) or (ii) if no other focus of infection was identiﬁed in the presence
of an intravascular catheter and/or if clinical signs of sepsis improved after line removal (probable). For
neutropenic patients with no deﬁnite clinical focus, mucosal translocation was presumed to be the origin
of the bacteremia, based on the deﬁnition from the Centers for Disease Control and Prevention
(http://www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf). In cases of recurrent infection, a fo-
cus was considered persistent if there was an unresolved deep source of infection or if a potentially
infected intravascular catheter was not removed between episodes of bacteremia. Ethical approval for
the study was obtained from the local Research Ethics Committee (reference no. 13/EE/0044), and the
need for informed consent was waived.
Twenty-one of the 44 isolates had been sequenced previously (27). For the 23 new E. faecium isolates
sequenced here, bacteria were cultured on Columbia blood agar (CBA; Oxoid) for 48 h at 37°C in air.
Phenotypic antimicrobial susceptibility testing for all 44 isolates was performed using a Vitek2 instrument
(bioMérieux, Marcy l’Etoile, France) with an AST-P607 card. DNA was extracted using a QIAxtractor
(Qiagen), and sequencing was performed on an Illumina HiSeq 2000 instrument. Sequence reads were
assembled using Velvet and annotated using Prokka. The pangenome was estimated using Roary (28)
with a 98% identiﬁcation (ID) cutoff. The van gene in the two patients with genetically related VREfm and
VSEfm isolates was extracted from the Roary pan genome and compared to the vanA gene extracted
from a vanA transposon (NCBI accession number M97297) and the vanB gene extracted from Aus0004
(NCBI accession number CP003351) using BLAST. The presence of antibiotic resistance genes was
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determined using an in-house curated version of the ResFinder database (genes are listed in Data Set S3)
(29) and ARIBA (https://github.com/sanger-pathogens/ariba/wiki).
Sequence data for an additional 263 E. faecium isolates associated with bloodstream infection in 263
patients at CUH between November 2006 and December 2012 and belonging to the hospital-adapted
clone of clade A based on whole-genome sequence analysis were taken from Raven et al. (27). These 263
genomes together with the 44 study genomes were mapped to E. faecium Aus0004 (NCBI accession
number CP003351) using SMALT (http://www.sanger.ac.uk/science/tools/smalt-0). Mobile genetic ele-
ments (identiﬁed based on annotation and PHAST [30]) and recombination events (identiﬁed using
Gubbins [31]) were removed to identify the core genome. A maximum-likelihood tree was created using
RAxML based on single nucleotide polymorphisms (SNPs) in the core genome. Pairwise SNP differences
were calculated based on SNPs in the core genome.
Accession number(s). The sequences determined for this study were deposited in the European
Nucleotide Archive under accession numbers ERR369962, ERR369975, ERR369979, ERR369980,
ERR369983, ERR369992, ERR370001, ERR370025, ERR370028, ERR375298, ERR375306, ERR375310,
ERR375319, ERR375322, ERR375348, ERR375405, ERR375413, ERR375440, ERR375455, ERR375476,
ERR375478, ERR375492, ERR375503, ERR375511, ERR375534, ERR375548, ERR377424, ERR377426,
ERR377429, ERR377430, ERR377432, ERR377434, ERR377441, ERR377443, ERR377453, ERR377456,
ERR377495, ERR377498, ERR377503, ERR377512, ERR388704, ERR388709, ERR388720, and ERR388721 (see
Data Set S1 in the supplemental material).
RESULTS
A retrospective review of patients at Cambridge University Hospitals NHS Founda-
tion Trust (CUH) between November 2006 and December 2012 identiﬁed 231 patients
with at least one episode of VREfm bacteremia. Of these, 14 patients had at least one
episode of recurrence, giving an estimated recurrence rate of 6.1%. We identiﬁed 12
patients that had isolates from at least two episodes of VREfm bacteremia available for
whole-genome sequencing (Table 1 summarizes patient data; see also Data Set S1 in
the supplemental material for information on individual isolates). Ten patients had
one recurrence, and two patients had two recurrences of bacteremia. To determine the
genetic relatedness of isolates causing recurrence, we identiﬁed single nucleotide
polymorphisms (SNPs) in the core genome based on mapping to a reference genome.
Of the 14 isolate pairs associated with a recurrent bacteremia, four (from four patients)
were closely related (1 to 7 SNPs; median, 1.5 SNPs) to the isolate from the previous
episode (Fig. 1A and Table 1). This ﬁnding is highly indicative of relapse (or reinfection)
with the same strain, based on a study that reported a genetic distance between E.
faecium carried by the same person (within-host diversity) of six core SNPs (24). In
contrast, 10 isolates (from 10 patients) were more genetically distant from the isolate
from the previous episode (25 to 368 SNPs; median, 258 SNPs), which is consistent with
reinfection by a different strain (Fig. 1A and Table 1). The two patients with two
recurrences of bacteremia had both an episode of relapse (pairwise SNP difference of
2 and 7 SNPs, respectively) and an episode of reinfection with a new strain (25 and 309
SNPs, respectively) (Table 1). The SNPs acquired between the ﬁrst and second isolate for
the four genetically related isolate pairs were located in different genes in different
patients (Table S1). The median time to ﬁrst recurrence across the study population was
80 days (range, 39 to 1,578 days), and the second episodes of recurrence occurred 36
and 168 days after the preceding bacteremia. Comparison of the timing of recurrence
with the genomic analyses indicated that all isolates from cases of relapse/reinfection
with the same strain were isolated within 108 days of each other, while recurrences due
to reinfection with a different strain were equally likely to occur within 108 days (5/10
episodes) and after 108 days (5/10).
All 12 study patients with recurrent bacteremia had multiple comorbidities that
predisposed to VREfm bacteremia (Table 1 and Data Set S1). The most probable source
for the bacteremia was deﬁned for each case (Table 1). Mucosal translocation (n  7,
with possible concurrent intravascular catheter infection) and intravascular catheters
(n 5) were the most common sources of bacteremia for the study patients. There was
no clear difference identiﬁed between the sources of infection in patients with recur-
rence due to the same or different strains (Tables 1 and S2). The four episodes of
recurrence due to the same strain were associated with presumed persistent intrave-
nous catheter colonization and/or gut carriage (n  3) or with failure to eradicate a
persistent focus of infection (n  1, chronic pyelonephritis associated with kidney
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stones) (Tables 1 and S2). A central venous catheter was known to be retained between
episodes of bacteremia in 2/10 cases with reinfection with a different strain, meaning
that whole-genome sequencing was able to refute these as being a persistent focus.
The retrospective review of CUH patients also identiﬁed nine patients with putative
mixed bloodstream infection with VREfm and VSEfm for whom both isolates were available
for whole-genome sequencing (Table 1). A pairwise core genome comparison of the 9
VREfm/VSEfm pairs revealed that 7/9 (78%) patients had isolate pairs that were genetically
distinct (median, 217 SNPs; range, 70 to 381 SNPs) (Fig. 1B), which is consistent with true
mixed-strain infection. The most common source of infection for patients with true mixed
infections was an intravascular catheter (4/7, or 57%). The remaining two patients had
isolates that were identical at the core genome level. Further analysis of the genetic content
between these two pairs through comparison to the ResFinder database conﬁrmed the
variable presence of the vanRSHAXYZ genes, which encode vancomycin resistance. There
was insufﬁcient sequence adjacent to the vanA transposon in the genome assemblies to
identify the genetic location of these genes, so differences in gene content between the
VREfm and VSEfm isolates in each pair were assessed. In one isolate pair (from patient 16)
the van genes had been lost together with 21 genes, including 7 genes best matched to
a plasmid (based on a BLAST search), suggesting that they may have been lost/gained
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FIG 1 Genetic relatedness of isolates from the same patient with recurrent bacteremia or with mixed infection with VREfm and VSEfm. (A) The right-hand graph
shows the pairwise core genome SNP difference between E. faecium isolates cultured from the same patient with recurrent bacteremia more than 30 days apart
and the timing of the episodes. Red indicates isolate pairs that were closely related (1 to 7 SNPs) based on genome sequence data. The left-hand graph
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together with part of a plasmid (Data Set S2). Two genes labeled as tetM and ermBwere lost
alongside the van genes in this patient, but both isolates retained a copy of tetM and ermB,
and so this may not have affected the wider antibiotic resistance phenotype (Fig. 2). In the
second isolate pair (from patient 21) an additional 14 genes had been lost with the van
genes, including ﬁve genes located adjacent in the genome (Data Set S2), suggesting that
vanA was not gained/lost as part of a plasmid but may have moved as part of a smaller
transposable element.
We evaluated whether the phenotypic antibiotic resistance proﬁle (antibiogram) to
11 drugs (excluding glycopeptides) could be used to distinguish between genetically
related and distinct strains from the same patient (Fig. 2). Of the six isolate pairs that
were closely related in the two study collections, four had identical antibiograms, one
varied by tetracycline resistance associated with gain/loss of the tetM gene, and one
varied between susceptible and intermediate resistance to quinupristin-dalfopristin
(Fig. 2). Of the 17 strain pairs that were genetically different, three had identical
antibiograms, and the remainder had between 1 and 5 (median, 2) differences (Fig. 2).
The most variable antibiotic was tetracycline (10/17 pairs), followed by high-level
resistance to streptomycin (n  7) and nitrofurantoin (n  6). Since 3/7 identical
antibiograms (43%) belonged to genetically distinct strains, this suggests that an
antibiogram does not reliably distinguish between genetically related and distinct
strains from the same patient. However, more than one change in the antibiogram was
identiﬁed only in genetically distinct strains (12/17 genetically distinct pairs).
The high rate of true mixed VREfm and VSEfm infection and of recurrence with a
new strain indicates carriage of multiple lineages or the acquisition of new strains over
time. Health care settings are associated with the acquisition of E. faecium, and so we
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FIG 2 Comparison of strain similarities based on genome sequence data and antibiograms. Two patients
with both relapse and reinfection occur twice in the list. Changes in antibiotic resistance between isolates
from the same patient are shown (red, change from susceptible to resistant; green, change from resistant
to susceptible; white, no change).
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investigated CUH as a putative source by combining the 44 study E. faecium genomes
with an additional 263 E. faecium genomes associated with bloodstream infection in
263 patients at the same hospital over the same time period (2006 to 2012) (Fig. S1).
Based on analysis of the combined genomes, 26 of the 44 study isolates were closely
related to at least one CUH isolate (0 to 8 SNPs; median, 3), including 3 isolates that
were closely related to an isolate from another study patient. This included isolates
from 6/7 patients infected with different VREfm and VSEfm strains and 6/10 patients
with recurrence caused by different strains. The remaining isolates were between 12
and 86 SNPs (median, 33 SNPs) from the closest genetic match.
DISCUSSION
This study represents the ﬁrst use of whole-genome sequencing in the context of E.
faecium bacteremia to investigate the relative rates of relapse and reinfection in
recurrent infections and to study mixed infection with VREfm and VSEfm. Although
rates of recurrence vary in the literature, the estimated rate of 6.1% identiﬁed at CUH
is within the range of rates reported previously (6–8).
We found that the majority of patients in our study had a recurrent VREfm bacteremia
caused by reinfection with a new strain. This ﬁnding supports that of Cheng et al. who
found reinfection to be responsible for 70% of recurrence based on PFGE although that
study focused primarily on E. faecalis (12). These reinfections could be due either to
persistent carriage of a genetically distinct strain or to reinfection with a newly acquired
strain. We found that at least 60% of reinfections were caused by isolates that were
genetically closely related to another bacteremia isolate from CUH, suggesting cross-
transmission in the hospital. Additionally, the rates of cross-transmission found in this study
are likely to be an underestimate since asymptomatic gut carriage and the environment
represent large reservoirs of VREfm and were not sampled in this study. These ﬁndings
suggest that the emphasis on preventing recurrent VREfm bacteremia should be on
infection control and minimizing periods of susceptibility to infection. Further studies will
be required to elucidate the role of the environment, staff, and patients as sources for these
hospital acquisitions to improve infection control.
The results of this study suggest that recurrence with the same strain may be related
to time. Episodes of recurrence with the same strain were identiﬁed only up to 108 days
apart, which concurs with ﬁndings by Baran et al. based on E. faecalis and E. faecium
isolates from a total of three patients (13). In contrast to our ﬁndings for same-strain
recurrence, our study showed that bacteremic episodes due to reinfections with a
distinct strain were roughly equally likely to occur within and after 108 days of each
other and as early as 57 days apart. Further work will be required using larger sample
sizes from multiple centers to determine whether there is a true relationship between
the relatedness of E. faecium strains causing recurrence and the time between episodes.
We also determined that the majority of patients with mixed VREfm and VSEfm
bacteremia were infected with two genetically distinct strains. This result differs from
the ﬁnding by Cardenas et al. that four patients had closely related VREfm and VSEfm
strains associated with bacteremia based on MLST (16). The true mixed infections in our
study frequently varied in antibiotic resistance proﬁles. While most cases of mixed
VREfm and VSEfm infection would be detected during routine disc susceptibility
testing, this variation in antibiotic resistance proﬁles could complicate treatment in
cases that go undetected. Although the numbers are low in our study, it was interesting
that true mixed VREfm and VSEfm infections were commonly suspected to originate
from an intravascular source, suggesting that central venous catheters may become
colonized with multiple strains of E. faecium.
The results of our study suggest that antibiograms lack accuracy in predicting the
genetic relatedness of strains. The utility of antibiograms for determining the related-
ness of E. faecium strains has not previously been evaluated, but our ﬁnding that a pair
of identical strains could vary in their resistance to antibiotics is consistent with the fact
that E. faecium has a highly mobile genome, with many resistance genes carried on
mobile genetic elements.
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Our study may have implications for future evaluation of VREfm treatment efﬁcacy.
There are currently no randomized controlled trials to deﬁne the optimal antibiotic for
the treatment of VREfm bacteremia. Current knowledge is based on retrospective
observational studies comparing linezolid to daptomycin, where recurrent infection is
often deﬁned as one of the outcome measures in the absence of bacterial typing results
(6, 8, 25). These studies imply that early recurrence (often assessed at 30 or 60 days after
treatment completion) is caused by true relapse (6, 8) or rely on phenotype, such as
identical antibiograms, to infer relapse (25). Our results show that in the absence of
prospective randomized studies or bacterial genotyping, one needs to question
whether a recurrent infection is indeed due to ineffective therapy and not due to
underlying, confounding patient-related factors conferring increased susceptibility to
reinfection. Future studies should address this issue.
This study has several limitations. We did not sequence multiple colonies from the
same sample to assess diversity, meaning that apparent reinfections could have been
mixed infections at the outset. The study samples were retrieved from frozen stock, and
it is not possible to know whether these were originally created from a single or
multiple colonies. It is not possible to differentiate between relapse and reinfection by
the same strain, introducing an element of uncertainty into our classiﬁcation. The true
level of mixed infection will be higher than we report here since we assessed only
patients with a VREfm and VSEfm mixed infection and analyzed one colony of each
from every bacteremic episode. Finally, the rate of recurrence identiﬁed here may be an
underestimate since repeat cultures were not taken systematically.
In conclusion, the ﬁndings of this study show that the majority of VREfm recurrences
and mixed VREfm and VSEfm infections are due to different strains and that antibi-
ograms lack accuracy in determining genetic relatedness. This observation has impor-
tant implications for infection control as it highlights the importance of reducing
cross-transmission in vulnerable patient groups.
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